Roche NimbleGen and BioDiscovery Form Strategic Alliance to Enhance CGH Microarrays, Software and Services

05.06.2008 | from F. Hoffmann-La Roche AG


F. Hoffmann-La Roche AG

05.06.2008, MADISON. Roche NimbleGen Inc., a company of Roche Applied Science, announced today that it has formed a strategic alliance with BioDiscovery, Inc. to offer complete solutions to comparative genomic hybridization (CGH) microarray customers. The new high-density 2.1 million probe (HD2) arrays of Roche NimbleGen combined with industry-leading proprietary software, Nexus Copy Number, of BioDiscovery bring unprecedented power and ease in whole-genome CGH analysis. As part of this alliance Roche NimbleGen and BioDiscovery will co-market and co-promote their products and services to scientists worldwide. The companies also plan to present data generated from NimbleGen CGH arrays using Nexus software of BioDiscovery to the research community through a series of seminars.

"This alliance with BioDiscovery will enable Roche NimbleGen to significantly enhance the customer experience by providing complete data analysis solutions for our customers using NimbleGen arrays for CGH analysis. At the same time we are excited about the opportunity to develop a strong business relationship with BioDiscovery in offering complete solutions to our customers in genomics and life sciences," said Srini Ramachandra, Senior Director for Software Marketing at Roche NimbleGen.

"We are thrilled about working with Roche NimbleGen in providing a complete and validated solution to our customers. The powerful combination of our technologies enables scientists to analyze data from millions of probes across thousands of samples to quickly arrive at important biological insights," said Dr. Soheil Shams, President of BioDiscovery. "We look forward to expanding our relationship with Roche NimbleGen and furthering the state of technology in genomics research."

Roche NimbleGen is a leading innovator, manufacturer, and supplier of a proprietary suite of DNA microarrays, consumables, instruments, and services. Roche NimbleGen uniquely produces high-density arrays of long oligo probes that provide greater information content and higher data quality necessary for studying the full diversity of genomic and epigenomic variation. The improved performance is made possible by proprietary Maskless Array Synthesis (MAS) technology of Roche NimbleGen, which uses digital light processing and rapid, high-yield photochemistry to synthesize long oligo, high-density DNA microarrays with extreme flexibility.

--- END press release Roche NimbleGen and BioDiscovery Form Strategic Alliance to Enhance CGH Microarrays, Software and Services ---


More information and links:
  F. Hoffmann-La Roche AG (company entry)



Swissnewsnow.com

On Swissnewsnow.com are published media releases, information from Swiss companies and Swiss authorities.

HELP Media AG on social networks
Facebook X (früher Twitter) Instagram LinkedIn YouTube

Subscription

Publish your media releases as a subscription and benefit from two free media releases.

Subscription 10 media releases (+2 free)
Subscription now »

Publish media release

To publish your own press release on Swissnewsnow.com, click on the following link:

Publish media release now »

Contact

Email:
info@help.ch

Address:
HELP Media AG
Thurgauerstrasse 40, 8050 Zurich


Copyright © 1996-2025 HELP Media AG, CH-8050 Zurich. All statements without guarantee. Terms and Conditions, Terms of Use & Privacy Policy